Changes in serum levels of glycoprotein tumor markers (e.g., CA15–3 and CA125) are associated with aberrant protein glycosylation in cancer cells, which may influence their expression levels, stability, or immunodetection. This evidence concerns the gene MUC16 and neoplasm.